Search results for "tamoxifen"

showing 10 items of 70 documents

Pharmacokinetics of Droloxifene and Its Metabolites in Breast Cancer Patients

1991

Pharmacokinetics and metabolism of droloxifene, a new antiestrogenic drug, have been investigated by single- and multiple-dose studies in postmenopausal patients with advanced breast cancer. Short terminal elimination half-life, low accumulation, and improved drug tolerability are the most striking features of this safe and effective new antiestrogen. Bioequivalence of film-coated tablet, tablet, and standard solution of droloxifene has been shown. The concentrations of droloxifene and its metabolites have been determined by a highly selective HPLC method.

AdultOncologyDrugCancer Researchmedicine.medical_specialtymedia_common.quotation_subjectAdministration OralBiological AvailabilityAntineoplastic AgentsBreast NeoplasmsBioequivalenceBreast cancerPharmacokineticsInternal medicinemedicineHumansChromatography High Pressure LiquidAgedmedia_commonAged 80 and overbusiness.industryEstrogen AntagonistsCancerMiddle AgedAntiestrogenmedicine.diseaseTamoxifenOncologyTolerabilityDroloxifeneDrug EvaluationFemalebusinessHalf-LifeAmerican Journal of Clinical Oncology
researchProduct

Quality of life and adjuvant tamoxifen treatment in breast cancer patients

2009

About two-thirds of all breast cancer patients are treated with adjuvant hormonal therapy. Side effects of tamoxifen and their effects on physical, emotional and social functioning have been shown to impair the quality of life. Aim of this paper was to evaluate the side effects and level of influence on the physical, emotional and social functioning caused by tamoxifen treatment. For assessment of quality of life an own questionnaire was designed. Between January 2001 and December 2003, 136 women with breast cancer and adjuvant tamoxifen therapy were included in this study. Data of side effects, physical and mental health and patients' self-evaluation identified detrimental effects on patie…

AdultOncologymedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.medical_treatmentBreast NeoplasmsBreast cancerQuality of lifeSurveys and QuestionnairesInternal medicineBody ImagemedicineHumansskin and connective tissue diseasesAgedAged 80 and overChemotherapyAdjuvant tamoxifenbusiness.industryMiddle Agedmedicine.diseaseMental healthTamoxifenOncologyChemotherapy AdjuvantQuality of LifeHormonal therapyFemalebusinessAdjuvantTamoxifenmedicine.drugEuropean Journal of Cancer Care
researchProduct

Acute abdomen due to endometriosis in a premenopausal woman taking tamoxifen.

2003

Tamoxifen exhibits agonistic properties on the uterus. We describe a premenopausal woman who, while having tamoxifen due to a diagnosis of in situ ductal carcinoma, developed endometriosis requiring surgery.

AdultSelective Estrogen Receptor Modulatorsmedicine.medical_specialtyAntineoplastic Agents HormonalEndometriosisUterusEndometriosisBreast NeoplasmsCarcinomamedicineHumansskin and connective tissue diseasesGynecologybusiness.industryCarcinoma Ductal BreastObstetrics and GynecologyDuctal carcinomamedicine.diseaseAntiestrogenAbdominal PainOvarian CystsTamoxifenmedicine.anatomical_structureReproductive MedicinePremenopauseAcute abdomenAcute DiseaseFemalemedicine.symptombusinesshormones hormone substitutes and hormone antagonistsTamoxifenmedicine.drugEuropean journal of obstetrics, gynecology, and reproductive biology
researchProduct

TGF-β signalling is required for CD4⁺ T cell homeostasis but dispensable for regulatory T cell function.

2013

Signalling by the cytokine TGF-β regulates mature CD4+ T cell populations but is not involved in the survival and function of regulatory T cells.

Autoimmunity10263 Institute of Experimental ImmunologyT-Lymphocytes RegulatoryMiceInterleukin 210302 clinical medicineTransforming Growth Factor beta2400 General Immunology and MicrobiologyHomeostasisCytotoxic T cellIL-2 receptorBiology (General)0303 health sciencesGeneral Neuroscience2800 General NeurosciencePeripheral toleranceFOXP3ColitisNatural killer T cell3. Good healthCell biologymedicine.anatomical_structureGeneral Agricultural and Biological SciencesResearch ArticleSignal TransductionRegulatory T cellQH301-705.5Receptors Antigen T-Cell610 Medicine & health1100 General Agricultural and Biological SciencesThymus GlandBiologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences1300 General Biochemistry Genetics and Molecular BiologyLymphopeniamedicineAnimalsAntigen-presenting cellCell Proliferation030304 developmental biologyInflammationIntegrasesGeneral Immunology and MicrobiologyReproducibility of ResultsMice Inbred C57BLTamoxifenImmunologyNIH 3T3 Cells570 Life sciences; biologyGene Deletion030215 immunologyPLoS Biology
researchProduct

β-Catenin Activation Regulates Tissue Growth Non–Cell Autonomously in the Hair Stem Cell Niche

2014

Coordinated Hair Growth Wnt/β-catenin signaling is a key pathway that plays a conserved role in regulating stem cell function during adult tissue regeneration. Using time-lapse imaging of live mice, Deschene et al. (p. 1353 ) show that genetic activation of β-catenin within hair follicle stem cells generates axes of hair growth by coordinated cell divisions and cell movements, even when the normal niches—the dermal papillae—are laser-ablated. Activated β-catenin enhances Wnt ligand secretion, and these ligands can then activate Wnt signaling in adjacent cells that do not have activated β-catenin, indicating how activated stem cells could influence neighboring cells during normal growth and …

Beta-cateninWnt ProteinCellular differentiationLigandBiologyLigandsModels BiologicalArticleMiceStem CellmedicineAnimalsStem Cell NicheAnimals; Cell Differentiation; Cell Division; Hair; Hair Follicle; Ligands; Mice; Models Biological; Mutation; Stem Cell Niche; Stem Cells; Tamoxifen; Up-Regulation; Wnt Proteins; beta Catenin; Wnt Signaling Pathway; Medicine (all); MultidisciplinaryWnt Signaling Pathwaybeta CateninMultidisciplinaryintegumentary systemAnimalStem CellsMedicine (all)Regeneration (biology)Mesenchymal stem cellWnt signaling pathwayCell DifferentiationHair follicleUp-RegulationCell biologyWnt ProteinsTamoxifenmedicine.anatomical_structureCateninMutationbiology.proteinStem cellHair FollicleCell DivisionHairScience
researchProduct

Hysteroscopic Evaluation of Endometrial Changes in Breast Cancer Women with or without Hormone Therapies: Results from a Large Multicenter Cohort Stu…

2020

ABSTRACT Study Objective The primary aim of our study was to investigate the incidence of endometrial pathologies, especially endometrial cancer, in women with breast cancer treated with tamoxifen (TAM), aromatase inhibitors (AIs), or receiving no treatment (NT). The secondary aim was to identify, in this cohort, ultrasonographic findings that represent robust indications for hysteroscopy and endometrial biopsy, to avoid unnecessary second-level diagnostic procedures. Design Multicenter retrospective cohort study (Clinical Trial ID: NCT03898947). Setting Data were collected from different Italian centers: Regina Elena National Cancer Institute of Rome, Arbor Vitae Centre of Rome, Gaetano Ma…

BiopsyAromatase inhibitors Breast cancer Endometrial cancer Endometrial pathologies Tamoxifen Adult Aged Aged 80 and over Antineoplastic Agents Hormonal Biopsy Breast Neoplasms Cohort Studies Endometrial Hyperplasia Endometrial Neoplasms Endometrium Female Humans Hysteroscopy Incidence Middle Aged Polyps Precancerous Conditions Pregnancy Retrospective Studies Tamoxifen Uterine Diseases Uterine NeoplasmsCohort StudiesEndometrium0302 clinical medicineBreast cancerEndometrial cancerPregnancyAromatase inhibitors; Breast cancer; Endometrial cancer; Endometrial pathologies; TamoxifenAged 80 and overUterine Diseases030219 obstetrics & reproductive medicinemedicine.diagnostic_testEndometrial pathologiesIncidenceObstetrics and GynecologyMiddle AgedAromatase inhibitorsHysteroscopy030220 oncology & carcinogenesisEndometrial HyperplasiaUterine NeoplasmsFemalemedicine.drugAromatase inhibitors Breast cancer Endometrial cancer Endometrial pathologies TamoxifenAdultmedicine.medical_specialtyAntineoplastic Agents HormonalBreast NeoplasmsHysteroscopy03 medical and health sciencesBreast cancerPolypsmedicineEndometrial PolypHumansAgedRetrospective StudiesGynecologybusiness.industryEndometrial cancerCancerRetrospective cohort studymedicine.diseaseEndometrial NeoplasmsTamoxifenbusinessPrecancerous ConditionsTamoxifenEndometrial biopsy
researchProduct

CtIP silencing as a novel mechanism of tamoxifen resistance in breast cancer.

2007

AbstractAcquired resistance to the antiestrogen tamoxifen constitutes a major clinical challenge in breast cancer therapy. However, the mechanisms involved are still poorly understood. Using serial analysis of gene expression, we identified CtIP, a BRCA1- and CtBP-interacting protein, as one of the most significantly down-regulated transcripts in estrogen receptor α–positive (ER+) MCF-7 tamoxifen-resistant breast cancer cells. We further confirmed the association of CtIP down-regulation with tamoxifen resistance in an additional ER+ breast cancer line (T47D), strengthening the relevance of the phenomenon observed. In additional studies, we found CtIP protein expression in a majority of ER+ …

Cancer ResearchAntineoplastic Agents HormonalEstrogen receptorDown-RegulationBreast NeoplasmsDisease-Free SurvivalBreast cancerCell Line TumormedicineGene silencingHumansSerial analysis of gene expressionGene Silencingskin and connective tissue diseasesMolecular BiologyEndodeoxyribonucleasesbusiness.industryCancerNuclear ProteinsAntiestrogenmedicine.diseaseGrowth InhibitorsGene Expression Regulation NeoplasticTamoxifenOncologyDrug Resistance NeoplasmCancer researchFemalebusinessCarrier ProteinsTamoxifenProgressive diseasemedicine.drugMolecular cancer research : MCR
researchProduct

Deletion of the PER3 Gene on Chromosome 1p36 in Recurrent ER-Positive Breast Cancer

2010

El pdf del artículo es la versión de autor.-- et al.

Cancer ResearchMicroarrayGene DosageGene ExpressionEstrogen receptorBreast NeoplasmsGene dosageMiceBreast cancerOriginal ReportsAnimalsHumansMedicineGenetic Predisposition to DiseaseCopy-number variationskin and connective tissue diseasesSequence Deletionbusiness.industryCancerPeriod Circadian ProteinsPrognosismedicine.diseaseSurvival AnalysisDisease Models AnimalReceptors EstrogenOncologyChromosomes Human Pair 1Cancer researchFemaleBreast diseaseNeoplasm Recurrence LocalbusinessTamoxifenmedicine.drugJournal of Clinical Oncology
researchProduct

Abstract 2935: Novel combination of repurposed drugs induces complete cell invasion arrest of glioblastoma in vitro

2019

Abstract Introduction: Glioblastoma multiforme (GBM) is an aggressive and lethal cancer with a poor prognosis even after conventional treatment (surgery, radiation, chemotherapy). Temozolomide (TMZ) is a standard cyotoxic agent used, despite resistance leading to recurrence. Therefore, additional strategies for targeting the tumor environment are needed. We demonstrate a combination of approved drugs (CAD) repurposed to target GBM leads to complete arrest of GBM cell invasion. Each drug in the combination individually targets diverse tumor pathways: 1) invasion via MMP2 (doxycycline); 2) angiogenesis, inflammation, and proliferation via p53-dependent G1 cell-cycle arrest (celecoxib); 3) aut…

Cancer ResearchProgrammed cell deathChemotherapyTumor microenvironmentMMP2TemozolomideAngiogenesisbusiness.industrymedicine.medical_treatmentCancermedicine.diseaseOncologymedicineCancer researchbusinessTamoxifenmedicine.drugCancer Research
researchProduct

Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription

2003

AbstractRecent efforts to develop pharmacologic agents that restore function to mutant forms of p53 hold significant promise in cancer therapy. Here, we examine the effects of such pharmacologic activation of p53 function using a small molecule, PRIMA-1, and a model system employing a p53 protein fused to a mutant steroid binding domain of the murine estrogen receptor (p53ERtam) that renders it responsive only in the presence of 4-hydroxytamoxifen. In either case, p53 activation triggered apoptosis that was not inhibited by the presence of macromolecular synthesis inhibitors. This p53-induced, transcription-independent apoptosis is Bax dependent, proceeds in the absence of a nucleus, and in…

Cancer ResearchTranscription GeneticRecombinant Fusion ProteinsMutantEstrogen receptorApoptosis03 medical and health sciencesMice0302 clinical medicineBcl-2-associated X proteinProto-Oncogene ProteinsTumor Cells CulturedAnimalsHumansCloning MolecularReceptorCells Cultured030304 developmental biologybcl-2-Associated X ProteinCell NucleusProtein Synthesis Inhibitors0303 health sciencesAza CompoundsbiologyCytochrome cCytochromes cCell BiologyFibroblastsBridged Bicyclo Compounds Heterocyclic3. Good healthCell biologyTransport proteinMitochondriaProtein TransportTamoxifenProto-Oncogene Proteins c-bcl-2Receptors EstrogenOncologyApoptosis030220 oncology & carcinogenesisMutationbiology.proteinTumor Suppressor Protein p53Binding domainCancer Cell
researchProduct